Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    dian ginsberg | parkinsons
Previous Study | Return to List | Next Study

Intravenous Plasma Treatment for Parkinson's Disease (yFFP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04202757
Recruitment Status : Completed
First Posted : December 18, 2019
Last Update Posted : January 5, 2022
Sponsor:
Collaborator:
Carolina Longevity Institute
Information provided by (Responsible Party):
The Neurology Center

Brief Summary:
This study will do a preliminary evaluation of a possible treatment for mild-to-moderate Parkinson's disease. Patients will be treated with either transfusions of plasma from young donors. or with placebo transfusions. In the following several months, Parkinson's symptoms will be monitored and compared for the two groups.

Condition or disease Intervention/treatment Phase
Idiopathic Parkinson Disease Biological: [21CFR640.30] Plasma from 18 - 25 year old volunteer donors Other: Saline Early Phase 1

Detailed Description:
This is a double-blind placebo controlled trial, designed to evaluate the efficacy of plasma from volunteer donors of ages 18-25. This young fresh frozen plasma (yFFP) will be given intravenously in two doses of 12.5 ml/kg each, with 40-56 hours between doses. In the following 24 weeks, Parkinson's symptoms will be monitored using the short version of the Stanford Presenteeism Scale (SPS-6), and a modified version of the UPDRS scale.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Placebo controlled trial
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description: Blinding will be achieved by preparing both yFFP and placebo (0.1% riboflavin in normal saline) solution into identical-sized, masked bags. The riboflavin is added to the saline to achieve indistinguishable color when compared to the yFFP. Physicians who evaluate patients are masked from treatment assignment.
Primary Purpose: Treatment
Official Title: Intravenous Young Fresh Frozen Plasma (yFFP) Investigational Treatment for Parkinson's Disease
Actual Study Start Date : September 14, 2018
Actual Primary Completion Date : August 7, 2019
Actual Study Completion Date : August 8, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Young Fresh Frozen Plasma (yFFP)
[21CFR640.30] Plasma from 18 - 25 year old volunteer donors
Biological: [21CFR640.30] Plasma from 18 - 25 year old volunteer donors
12.5 ml/kg intravenous Spectrum Plasma yFFP, per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
Other Name: Young Fresh Frozen Plasma (yFFP)

Placebo Comparator: Saline
0.1% riboflavin in normal saline
Other: Saline
12.5 ml/kg intravenous 0.9% sodium chloride with 0.1% riboflavin , per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
Other Name: Normal saline




Primary Outcome Measures :
  1. Changes in Physician assessment [ Time Frame: Two weeks prior to infusion, at one-three-six months post-infusion ]
    Unified Parkinson Disease Rating Scale (UPDRS)

  2. Patient assessment [ Time Frame: Two weeks prior to infusion, at one-three-six months post-infusion ]
    Changes in Stanford Presenteeism Scale (SPS)


Secondary Outcome Measures :
  1. Stability of administration [ Time Frame: At the time of infusions, day 1 and day 2 ]
    Adverse events (if any)

  2. Factors predicting a beneficial response [ Time Frame: After the last participant's final contact at 6 months ]
    Patient Global Impression of change



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Parkinson's disease
  • Disease duration of 1 to 5 years
  • Willingness to confirm the use of adequate birth control while on the trial will be required in premenopausal women without evidence for an inability to become pregnant.
  • Willingness to not start any other treatment for Parkinson's or Multiple Sclerosis during the parallel part of the trial.

Exclusion Criteria:

  • Other significant disease, which in the view of the study doctor may make assessment of the efficacy of yFFP difficult.
  • Unstable medical conditions.
  • Must weigh at least 45.5 kg. Cannot weigh more than 130 kg.
  • A severe disease state diagnosis
  • Litigation. Patients in litigation will be excluded only if conclusion of that litigation is imminent during the course of the study.
  • If patient is pregnant or breastfeeding.
  • Complete IgA deficiency.
  • Rare contraindications to yFFP therapy as per summary of product characteristics.
  • Receiving yFFP for other reasons.
  • Ongoing drug or alcohol abuse.
  • Psychiatric disorder that could, in the judgement of the site investigator, interfere with successful study participation.
  • Unwillingness or inability to complete the study or an inability to understand the questionnaires being used.
  • Cancer other than basal cell carcinoma within the last 5 years. However, those patients who have received definitive treatment, such as curative surgery more than 6 months ago, with no known recurrence can be included.
  • A history of hypercoagulable or thrombophilic clotting abnormalities.
  • A history of thromboembolic events: ischaemic stroke, confirmed myocardial infarction, pulmonary embolism; deep venous thrombosis except where immobility related (for example, after injury or operation).
  • Unstable angina pectoris.
  • Medications that might react with yFFP such as blood thinners
  • Renal failure or serum creatinine greater than 1.5 times the upper limit of normal at screening.
  • Any medical condition that, in the opinion of the investigator, would make it unsafe for the patient to participate or which would interfere with assessment of the outcome measures.
  • Participation in another interventional trial within 3 months of randomization. Participation in non-interventional studies is not a reason for exclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04202757


Locations
Layout table for location information
United States, Texas
The Neurology Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
The Neurology Center
Carolina Longevity Institute
Investigators
Layout table for investigator information
Principal Investigator: Dian Ginsberg, M.D. The Ginstitute of Functional Medicine
  Study Documents (Full-Text)

Documents provided by The Neurology Center:
Informed Consent Form  [PDF] February 7, 2020

Layout table for additonal information
Responsible Party: The Neurology Center
ClinicalTrials.gov Identifier: NCT04202757    
Other Study ID Numbers: NeurologyCenter
First Posted: December 18, 2019    Key Record Dates
Last Update Posted: January 5, 2022
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases